New York, New York 10016

  • Lung Cancer


Phase I trial to study the effectiveness of radiation therapy plus topotecan in treating patients who have non-small cell lung cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy and radiation therapy may kill more tumor cells.

Study summary:

OBJECTIVES: I. Determine the maximum tolerated dose of topotecan and chest irradiation in patients with non-small cell lung cancer. II. Determine the qualitative and quantitative toxic effects of this regimen in these patients. III. Determine the degree of antitumor activity of this regimen in these patients. OUTLINE: This is a dose escalation study of topotecan and thoracic radiotherapy. Beginning on day 1, patients receive topotecan IV continuously for 3-6 weeks and thoracic radiotherapy 5 days a week for 2, 3, or 6 weeks. Cohorts of 4-6 patients receive escalating doses of topotecan and thoracic radiotherapy until the maximum tolerated dose (MTD) of each therapy is determined. The MTD is defined as the dose preceding that at which 2 of 4 or 6 patients experience dose-limiting toxicity. Six additional patients are treated at the MTD. Patients who fail to achieve complete remission (CR) and continue to have measurable disease at 4-6 weeks after completion of radiotherapy receive topotecan IV continuously on days 1-21 at 1 dose level preceding the MTD as determined by the ongoing Protocol NYU-9123. Treatment continues every 4 weeks in the absence of unacceptable toxicity.


DISEASE CHARACTERISTICS: - Histologically proven non-small cell lung cancer - Eligible for chest irradiation with 3,000 to 6,000 cGy (based upon standard radiotherapy indications) - Measurable or evaluable disease - Measurable disease defined as bidimensionally measurable lesion on physical exam or radiograph (CT or MRI acceptable) PATIENT CHARACTERISTICS: - Age: 18 and over - Performance status: 0-2 - Life expectancy: At least 12 weeks - WBC at least 4,000/mm3 - Platelet count at least 100,000/mm3 - Bilirubin no greater than 1.5 mg/dL - AST less than 3 times normal - Alkaline phosphatase less than 3 times normal - Creatinine no greater than 1.5 mg/dL - Not pregnant or nursing PRIOR CONCURRENT THERAPY: - No more than 1 prior chemotherapy regimen allowed - At least 4 weeks since prior chemotherapy and recovered - No prior radiotherapy - Recovered from toxic effects of any prior therapy



Primary Contact:

Study Chair
Howard S. Hochster, MD
New York University School of Medicine

Backup Contact:


Location Contact:

New York, New York 10016
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: June 17, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.